Myosin VI contributes to malignant proliferation of human glioma cells.
10.4196/kjpp.2016.20.2.139
- Author:
Rong XU
1
;
Xu hao FANG
;
Ping ZHONG
Author Information
1. Neurosurgical Department of Huashan Hospital, Fudan University, Shanghai 200040, China. dr_zhongping@163.com
- Publication Type:Retracted Publication ; In Vitro ; Original Article
- Keywords:
Cell cycle;
Glioma;
Myosin VI;
Proliferation;
ShRNA
- MeSH:
Actins;
Cell Cycle;
Cell Proliferation;
Glioblastoma;
Glioma*;
Humans*;
Myosins*;
Prostatic Neoplasms;
RNA, Small Interfering
- From:The Korean Journal of Physiology and Pharmacology
2016;20(2):139-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
Previously characterized as a backward motor, myosin VI (MYO6), which belongs to myosin family, moves toward the minus end of the actin track, a direction opposite to all other known myosin members. Recent researches have illuminated the role of MYO6 in human cancers, particularly in prostate cancer. However, the role of MYO6 in glioma has not yet been determined. In this study, to explore the role of MYO6 in human glioma, lentivirus-delivered short hairpin RNA (shRNA) targeting MYO6 was designed to stably down-regulate its endogenous expression in glioblastoma cells U251. Knockdown of MYO6 signifi cantly inhibited viability and proliferation of U251 cells in vitro. Moreover, the cell cycle of U251 cells was arrested at G0/G1 phase with the absence of MYO6, which could contribute to the suppression of cell proliferation. In conclusion, we firstly identified the crucial involvement of MYO6 in human glioma. The inhibition of MYO6 by shRNA might be a potential therapeutic method in human glioma.
